A groundbreaking new study from Northwestern University offers a beacon of hope for the millions worldwide living with spinal cord injuries. Researchers have successfully used lab-grown human spinal cord tissue – sophisticated organoids created from stem cells – to model injury and, crucially, to test a novel therapy that promotes significant tissue repair. The findings, published February 11 in Nature Biomedical Engineering, demonstrate substantial nerve regrowth and a reduction in scarring, suggesting a potential path toward restoring function after debilitating spinal cord trauma.
The research centers around “dancing molecules,” a therapy previously shown to reverse paralysis in animal models. These molecules, designed to move dynamically and interact with cells, appear to stimulate the regrowth of neurites – the long extensions of neurons that allow for communication – and diminish the formation of glial scars, dense tissue that blocks nerve regeneration. The U.S. Food and Drug Administration (FDA) recently granted the therapy Orphan Drug Designation, recognizing its potential to treat a rare condition, which could expedite its development, and availability.
A More Realistic Model for Spinal Cord Injury
One of the most significant aspects of this research is the advanced model used to study spinal cord injuries. Although other scientists have created spinal cord organoids, the Northwestern team’s model is the most sophisticated to date, accurately mimicking the complex biological responses to trauma. The organoids, measuring several millimeters across, were engineered to include not only neurons and astrocytes, but as well microglia – immune cells crucial to the inflammatory response following injury. “We were the first to introduce microglia into a human spinal cord organoid,” explained Samuel I. Stupp, the study’s senior author and Board of Trustees Professor of Materials Science and Engineering, Chemistry, Medicine and Biomedical Engineering at Northwestern University. “That means that our organoid has all the chemicals that the resident immune system produces in response to an injury. That makes it a more realistic, accurate model of spinal cord injury.”
Researchers created two types of injury within the organoids: a laceration mimicking a surgical wound and a compressive contusion, similar to the trauma experienced in car accidents or falls. Both injury types resulted in cell death and glial scar formation, mirroring what happens in the human body. The team could even distinguish between healthy astrocytes and those forming the scar tissue, and detected the production of chondroitin sulfate proteoglycans, molecules associated with injury and disease in the nervous system.
“Dancing Molecules” Show Promise in Lab Tests
The “dancing molecules” therapy, first introduced in 2021, utilizes supramolecular therapeutic peptides (STPs) – large assemblies of molecules designed to activate cell receptors and stimulate the body’s natural repair mechanisms. The key to their effectiveness, according to Stupp, lies in their motion. “Given that cells themselves and their receptors are in constant motion, you can imagine that molecules moving more rapidly would encounter these receptors more often,” he said in a 2021 statement. “If the molecules are sluggish and not as ‘social,’ they may never arrive into contact with the cells.”
In the organoid experiments, the therapy delivered via a liquid injection that formed a nanofiber scaffold, significantly reduced inflammation, shrank glial scarring, and stimulated neurite extension. The researchers observed neurons growing in organized patterns, a crucial step toward restoring communication pathways severed by injury. This regrowth resembles the axon regeneration seen in previous animal studies, bolstering confidence in the therapy’s potential for human application.
Looking Ahead: From Organoids to Clinical Trials
The Northwestern team is already planning to refine their organoid models, engineering more advanced versions to replicate chronic, long-standing injuries, which often involve thicker and more persistent scar tissue. They also envision a future where these miniature spinal cords could be used to generate implantable tissue from a patient’s own stem cells, minimizing the risk of immune rejection and paving the way for personalized medicine approaches to spinal cord repair.
The study, “Injury and therapy in a human spinal cord organoid,” was supported by the Center for Regenerative Nanomedicine at Northwestern University and a gift from the John Potocsnak Family for spinal cord injury research. While clinical trials are still needed to confirm the safety and efficacy of the “dancing molecules” therapy in humans, these findings represent a major step forward in the quest to overcome the devastating effects of spinal cord injuries. The next step for the research team will be to further refine the organoid models and prepare for potential human studies, a process that will require significant funding and regulatory approval.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or someone you know been affected by spinal cord injury? Share your thoughts and experiences in the comments below. And please, share this article to help spread awareness of this promising research.
